Cox Regression News Today

In a recent study published in the Lancet, researchers evaluated the safety and efficacy of tixagevimab–cilgavimab, a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-neutralizing monoclonal antibody (mAb) combination in patients with mild to moderate coronavirus disease 2019 (COVID-19).

Research Article The prognostic value of serum albumin levels and respiratory rate for community-acquired pneumonia: A prospective, multi-center study Lili Zhao , Roles Formal analysis, Methodology, Writing – original draft Affiliation Department of Respiratory and Critical Care Medicine, Peking University People’s Hospital, Beijing, People’s Republic of China ⨯ Jing Bao , Roles Formal analysis, Methodology, Writing – original draft Affiliatio...